Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More
DISHMAN PHARMA | PROCTER & GAMBLE HEALTH | DISHMAN PHARMA/ PROCTER & GAMBLE HEALTH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | 62.2 | 40.3% | View Chart |
P/BV | x | 3.3 | 7.7 | 43.7% | View Chart |
Dividend Yield | % | 0.7 | 6.2 | 10.7% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
PROCTER & GAMBLE HEALTH Dec-18 |
DISHMAN PHARMA/ PROCTER & GAMBLE HEALTH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 3,549 | 10.5% | |
Low | Rs | 129 | 1,301 | 9.9% | |
Sales per share (Unadj.) | Rs | 197.8 | 511.4 | 38.7% | |
Earnings per share (Unadj.) | Rs | 21.2 | 61.3 | 34.6% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 74.0 | 46.9% | |
Dividends per share (Unadj.) | Rs | 2.00 | 440.00 | 0.5% | |
Dividend yield (eoy) | % | 0.8 | 18.1 | 4.4% | |
Book value per share (Unadj.) | Rs | 179.9 | 927.8 | 19.4% | |
Shares outstanding (eoy) | m | 80.69 | 16.60 | 486.1% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 4.7 | 26.8% | |
Avg P/E ratio | x | 11.9 | 39.6 | 30.0% | |
P/CF ratio (eoy) | x | 7.2 | 32.8 | 22.1% | |
Price / Book Value ratio | x | 1.4 | 2.6 | 53.5% | |
Dividend payout | % | 9.4 | 717.9 | 1.3% | |
Avg Mkt Cap | Rs m | 20,306 | 40,257 | 50.4% | |
No. of employees | `000 | 0.8 | 1.1 | 73.1% | |
Total wages/salary | Rs m | 5,355 | 1,313 | 407.9% | |
Avg. sales/employee | Rs Th | 19,252.7 | 7,486.7 | 257.2% | |
Avg. wages/employee | Rs Th | 6,459.5 | 1,157.6 | 558.0% | |
Avg. net profit/employee | Rs Th | 2,064.1 | 897.2 | 230.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 8,490 | 188.0% | |
Other income | Rs m | 265 | 244 | 108.8% | |
Total revenues | Rs m | 16,226 | 8,734 | 185.8% | |
Gross profit | Rs m | 4,103 | 1,482 | 276.9% | |
Depreciation | Rs m | 1,091 | 211 | 516.4% | |
Interest | Rs m | 944 | 0 | - | |
Profit before tax | Rs m | 2,334 | 1,514 | 154.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 66 | 0.0% | |
Tax | Rs m | 624 | 563 | 110.9% | |
Profit after tax | Rs m | 1,711 | 1,017 | 168.2% | |
Gross profit margin | % | 25.7 | 17.5 | 147.3% | |
Effective tax rate | % | 26.7 | 37.1 | 71.9% | |
Net profit margin | % | 10.7 | 12.0 | 89.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 15,343 | 71.8% | |
Current liabilities | Rs m | 9,517 | 1,960 | 485.5% | |
Net working cap to sales | % | 9.4 | 157.6 | 6.0% | |
Current ratio | x | 1.2 | 7.8 | 14.8% | |
Inventory Days | Days | 110 | 49 | 226.7% | |
Debtors Days | Days | 35 | 28 | 122.5% | |
Net fixed assets | Rs m | 16,304 | 1,209 | 1,348.2% | |
Share capital | Rs m | 161 | 166 | 97.2% | |
"Free" reserves | Rs m | 12,907 | 15,235 | 84.7% | |
Net worth | Rs m | 14,516 | 15,401 | 94.2% | |
Long term debt | Rs m | 4,189 | 0 | - | |
Total assets | Rs m | 29,805 | 17,595 | 169.4% | |
Interest coverage | x | 3.5 | NM | - | |
Debt to equity ratio | x | 0.3 | 0 | - | |
Sales to assets ratio | x | 0.5 | 0.5 | 111.0% | |
Return on assets | % | 8.9 | 5.8 | 154.1% | |
Return on equity | % | 11.8 | 6.6 | 178.4% | |
Return on capital | % | 17.5 | 10.3 | 170.9% | |
Exports to sales | % | 24.8 | 0 | - | |
Imports to sales | % | 3.7 | 0 | - | |
Exports (fob) | Rs m | 3,956 | NA | - | |
Imports (cif) | Rs m | 596 | NA | - | |
Fx inflow | Rs m | 4,952 | 1,636 | 302.6% | |
Fx outflow | Rs m | 697 | 4,368 | 16.0% | |
Net fx | Rs m | 4,255 | -2,732 | -155.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | -1,304 | -213.7% | |
From Investments | Rs m | -1,529 | 12,697 | -12.0% | |
From Financial Activity | Rs m | -941 | -301 | 313.2% | |
Net Cashflow | Rs m | 316 | 11,093 | 2.9% |
Indian Promoters | % | 61.4 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 51.8 | - | |
Indian inst/Mut Fund | % | 3.7 | 18.2 | 20.3% | |
FIIs | % | 12.7 | 1.0 | 1,270.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 29.1 | 75.9% | |
Shareholders | 46,261 | 28,591 | 161.8% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: CIPLA PFIZER NATCO PHARMA NEULAND LABS SANOFI INDIA
Compare DISHMAN PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Extending losses to the fifth straight session, Indian share markets witnessed selling pressure throughout the day today and ended deep in the red.
For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.
For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.
For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.
Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.
For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More